Oncosil Medical Ltd has released a press release.
Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from OncoSil Medical
- Trading Halt
- OncoSil receives $1.84m R&D tax incentive
- OSPREY Analysis Shows Survival Benefit for OncoSil Patients
- Response to ASX Aware Letter
- Positive Preliminary Results from PANCOSIL Phase 1-2 Study
Later from OncoSil Medical
- $8.0 million Capital Raise for Ongoing Commercial Expansion
- Prospectus
- Capital Raising Presentation
- CEO Remuneration Update
- Appendix 4D and Half Year Accounts
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical